Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation. Hospital Rio Hortega, University of Valladolid, Valladolid, Spain.
J Gastrointest Surg. 2012 Jun;16(6):1194-8. doi: 10.1007/s11605-012-1829-2. Epub 2012 Feb 4.
The high variation in responses to bariatric surgery might be partially explained by genetic effects. Recently, common polymorphisms of the fat mass and obesity-associated gene (FTO) have been linked to obesity in some populations. Only two studies have investigated the effect of FTO variants on weight loss of morbid obese patients undergoing bariatric surgery with contradictory results.
We decided to investigate the role of the rs9939609 FTO gene polymorphism on outcomes after a biliopancreatic diversion surgery (BPD) in morbidly obese patients.
A sample of 119 morbidly obese patients' body mass index (BMI) > 40 kg/m(2) were operated. Weight, fat mass, blood pressure, basal glucose, triacylglycerols, total cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol were measured at basal visit and at each visit (basal, 3, 9 and 12 months). The frequency of metabolic comorbidities was recorded at each visit.
Thirty-seven patients (31.1%) had genotype TT (wild type group), 58 (48.7%) patients had genotype TA and 24 patients (20.2%) had genotype AA. In the wild and mutant type groups, BMI, weight, waist circumference, systolic blood pressure and diastolic blood pressure decreased in a significant way. In the wild type groups, glucose, total cholesterol, low density lipoprotein (LDL) cholesterol and triacylglycerol concentrations decreased at 3, 9 and 12 months after surgery. In the mutant type groups, glucose, total cholesterol and triacylglycerol concentrations decreased at 3, 9 and 12 months after surgery. LDL cholesterol decreased at 9 and 12 months after surgery. Initial weight percent loss at 3 months of follow-up was higher in the wild type group (26.1% vs. 18.6%: p < 0.05). The initial weight percent loss at 9 or 12 months was similar in both genotypes.
Our study showed a higher initial weight loss at 3 months after the TT variant of FTO gene (rs9939609). However, the weight loss at 9 and 12 months of BPD was similar in both genotypes with a significant improvement in biochemical parameters and cardiovascular comorbidities.
减重手术的反应存在高度变异性,部分原因可能与遗传因素有关。最近,肥胖相关基因(FTO)的常见多态性已被证明与某些人群的肥胖有关。仅有两项研究调查了 FTO 变体对接受减重手术的病态肥胖患者体重减轻的影响,但结果存在争议。
我们决定研究 FTO 基因 rs9939609 多态性在病态肥胖患者接受胆胰分流术后的作用。
119 名病态肥胖患者的体重指数(BMI)>40kg/m2 接受手术。在基线就诊时和每次就诊时(基线、3、9 和 12 个月)测量体重、体脂肪量、血压、基础血糖、三酰甘油、总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇。每次就诊时记录代谢合并症的频率。
37 名患者(31.1%)为 TT 基因型(野生型组),58 名患者(48.7%)为 TA 基因型,24 名患者(20.2%)为 AA 基因型。在野生型和突变型组中,BMI、体重、腰围、收缩压和舒张压均显著下降。在野生型组中,术后 3、9 和 12 个月血糖、总胆固醇、低密度脂蛋白(LDL)胆固醇和三酰甘油浓度下降。在突变型组中,术后 3、9 和 12 个月血糖、总胆固醇和三酰甘油浓度下降,术后 9 和 12 个月 LDL 胆固醇下降。随访 3 个月时,野生型组初始体重百分比下降较高(26.1%比 18.6%:p<0.05)。两种基因型在 9 或 12 个月时的初始体重百分比下降相似。
我们的研究表明,FTO 基因(rs9939609)TT 变异在术后 3 个月时体重下降幅度更高。然而,两种基因型的 BPD 在 9 和 12 个月时的体重减轻相似,且生化参数和心血管合并症均显著改善。